Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adaptimmune Therapeutics (ADAP)
NASDAQ:ADAP
RESEARCH TOOLSreports
Holding ADAP?
Track your performance easily
ADAP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.53 - $2.05
Previous CloseN/A
Volume813.54K
Average Volume (3M)2.49M
Market Cap
$158.65M
Enterprise Value$131.49M
Total Cash (Recent Filing)$181.47M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Feb 27, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding255,883,210
10 Day Avg. Volume2,505,706
30 Day Avg. Volume2,487,412
Standard Deviation0.48
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.91
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue0.75
Enterprise Value/Gross Profit2.18
Enterprise Value/Ebitda-3.88
Forecast
1Y Price Target
$2.53Price Target Upside321.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Adaptimmune Therapeutics News
PremiumCompany Announcements
Adaptimmune Therapeutics Announces Key Leadership Changes
PremiumCompany Announcements
Adaptimmune’s Strategic Shift and Financial Update
PremiumPre-Earnings
Is ADAP a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Clinical Study SuccessLete-cel demonstrated an overall response rate of 42% in clinical studies, significantly outperforming current therapies.
Regulatory Approval And Market AdoptionTecelra's FDA approval has been well-received, with multiple inquiries from medical professionals, indicating strong market interest.
Strategic Restructuring And Financial OutlookADAP announced a strategic restructuring plan that will result in approximately $300M in cost savings from 2025-2028 with the goal of becoming operating breakeven during 2027.
Bears Say
Research And DevelopmentThe discontinuation of enrollment in the SURPASS-3 study due to a reallocation of resources means the full dataset anticipated in 2026 will no longer be available.
Sales PerformanceZero sales were reported for the Tecelra launch, and no meaningful revenue is expected shortly.
Workforce ReductionA 33% workforce reduction was announced as a necessary measure to help the company achieve break-even.
---
Ownership Overview
48.55% Insiders
0.10% Mutual Funds
0.01% Other Institutional Investors
51.08% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ADAP FAQ
What was Adaptimmune Therapeutics’s price range in the past 12 months?
Adaptimmune Therapeutics lowest stock price was $0.53 and its highest was $2.05 in the past 12 months.
What is Adaptimmune Therapeutics’s market cap?
Adaptimmune Therapeutics’s market cap is $158.65M.
When is Adaptimmune Therapeutics’s upcoming earnings report date?
Adaptimmune Therapeutics’s upcoming earnings report date is Feb 27, 2025 which is in 43 days.
How were Adaptimmune Therapeutics’s earnings last quarter?
Adaptimmune Therapeutics released its earnings results on Nov 13, 2024. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of -$0.009 by -$0.001.
Is Adaptimmune Therapeutics overvalued?
According to Wall Street analysts Adaptimmune Therapeutics’s price is currently Undervalued.
Does Adaptimmune Therapeutics pay dividends?
Adaptimmune Therapeutics does not currently pay dividends.
What is Adaptimmune Therapeutics’s EPS estimate?
Adaptimmune Therapeutics’s EPS estimate is -0.03.
How many shares outstanding does Adaptimmune Therapeutics have?
Adaptimmune Therapeutics has 255,883,210 shares outstanding.
What happened to Adaptimmune Therapeutics’s price movement after its last earnings report?
Adaptimmune Therapeutics reported an EPS of -$0.01 in its last earnings report, missing expectations of -$0.009. Following the earnings report the stock price went down -23.377%.
Which hedge fund is a major shareholder of Adaptimmune Therapeutics?
Currently, no hedge funds are holding shares in ADAP
---
Adaptimmune Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.53 (321.67% Upside)
$2.53 (321.67% Upside)
Blogger Sentiment
Bullish
ADAP Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 3.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.61%
12-Months-Change
Fundamentals
Return on Equity
-56.17%
Trailing 12-Months
Asset Growth
7.01%
Trailing 12-Months
Company Description
Adaptimmune Therapeutics
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
---
ADAP Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with strong results from clinical trials and a successful product launch, alongside strategic restructuring to achieve financial stability. However, challenges include significant job cuts and discontinuation of certain programs.Read More>---
ADAP Stock 12 Month Forecast
Average Price Target
$2.53
▲(321.67% Upside)
Technical Analysis
Best Analysts Covering ADAP
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+19.69%
reiterated a sell rating 2 months ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +19.69% per trade.
---